Initial human experience with MK-462 (rizatriptan): A novel 5-HT(1D) agonist

British Journal of Clinical Pharmacology

Volumn 43, Issue 1, 1997, Pages 49-54

  Sciberras, David G ^a,c   Polvino, William J ^a   Gertz, Barry J ^a   Cheng, Haiyung ^a   Stepanavage, Michael ^a   Wittreich, Johanna ^a   Olah, Timothy ^a   Edwards, Mark ^b   Mant, Timothy ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Guy's Drug Research Unit Ltd   (United Kingdom)

^c NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

5 HT(1D); Migraine; MK 462; Pharmacokinetics; Rizatriptan; Serotonin

Indexed keywords

GROWTH HORMONE; PROLACTIN; RIZATRIPTAN; SEROTONIN 1 AGONIST; SEROTONIN 1D RECEPTOR; SUMATRIPTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

EID: 0031019868     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1997.tb00137.x     Document Type: Article

References (35)

1. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalatgia 1988; 8(Suppl. 7): 19-28.
2. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States: relation to age, income, race, and other sociodemographic factors. JAMA 1992; 267: 64-69.
3. Osterhaus JT, Gutterman DL, Platchetka JR. Labor costs associated with migraine headaches. Pharmacother 1991; 11: 98-99.
4. Perrin VL. Clinical pharmacokinetics of ergotamine in migraine and cluster headache. Clin Pharmacokinet 1985; Jul-Aug 10(4): 334-353.
5. Patten JP for the Oral Sumatriptan Dose-defining Study Group. Clinical experience with oral sumatnptan: a placebocontrolled, dose-ranging study. J Neurol 1991: 238: S62-S65.
6. Goadsby PJ, Zagami AS, Donnan GA, et al. Oral sumatriptan in acute migraine. Lancet 1991; 338: 782-783.
7. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991; 265: 2831-2835.
8. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991; 325: 316-321.
9. Nielsen TH, Tfelt-Hansen P. Lack of effect of GR43175 on peripheral arteries in man. Cephalalgia 1989; 9(Suppl 9): 93-95.
10. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and cafergot in the acute treatment of migraine. Eur Neurol 1991; 31: 314-322.
11. Humphrey PPA, Feniuk W. Mode of action of the antimigraine drug sumatriptan. Trends Pharmacol Sci 1991; 12: 444-445.
12. Ferrari MD, Saxena PRS. Clinical effects and mechanism of action of sumatriptan in migraine. Clin Neurol Neurosurg 1992; 94(Suppl.): S73-S77.
13. 1-like agonists in the treatment of migraine. J Neurol 1991; 238: S57-S61.
14. 1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. Br J Pharmacol 1991; 102. 323-330.
15. Perren MJ, Feniuk W, Humphrey PPA. The selective closure of feline carotid arteriovenous anastomoses (AVAs) by GR43175. Cephalalgia 1989; Suppl. 9: 41-46.
16. Feniuk W, Humphrey PPA, Perren MJ. The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs. Br J Pharmacol 1989; 96: 83-90.
17. Friberg L, Olesen J, Iversen HK, Sperling B. Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet 1991; 338: 13-17.
18. Buzzi GM, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990; 99: 202-206.
19. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992; 13: 307-311.
20. Raskin NH. Serotonin receptors and headache. N Engl J Med 1991; 325: 353-354.
21. Humphrey PPA, Feniuk W, Marriott AS, Tanner RJN, Jackson MR, Tucker ML. Preclinical studies on the antimigraine drug, sumatriptan. Eur Neurol 1991; 31: 282-290.
22. 1D receptor agonist MK-462. Cephalalgia 1995; 15(Suppl. 14): 203.
23. 1D receptor agonist MK-462. Cephalalgia 1995; 15(Suppl. 14): 205.
24. Rolandi E, Franceschini R, Cataldi A, Barreca T. Endocrine effects of sumatriptan. Lancet 1992; 339: 1365.
25. 1983 Metropolitan height and weight tables. Stat Bull Metrop Life Found 1983; 64: 3-9.
26. 1D agonists MK-462 and sumatriptan in plasma by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. Presented at 11th Montreux Symposium, Montreux Switzerland, February 1, 1994.
27. Rocci ML, Jusko WJ. LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed 1983; 16: 203-216.
28. Renkin EM, Gilmore JP. In Handbook of Physiology: Renal Physiology, eds Orlorf J, Berliner RW, and Geiger SR, Washington, D.C.: American Physiology Society, 1973: 198.
29. 1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 1993; 87: 401-405.
30. Visser WH, Terwindt GM, Reines SA, et al. Rizatriptan (MK-462) versus sumatriptan in the acute treatment of migraine: a placebo-controlled, dose-ranging study. Arch Neurol 1996: (in press).
31. Cheng H, Polvino WJ, Sciberras D, et al. Pharmacokinetics and food interaction of MK-462 in healthy males. Biopharm Drug Dispos 1996; 17: 17-24.
32. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJN, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31: 291-294.
33. Dahlof C. Headache recurrence after subcutaneous sumatriptan. Lancet 1992; 339: 425-426.
34. Ferrari MD, Saxena PR. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol Sci 1993; 14: 129-133.
35. Weindl A, Sofroniew MV. Relation of neuropeptides to mammalian circumventricular organs. In Neurosecretion and Brain Peptides, eds Martin JB, Reichlin S, and Bick, KL, New York: Raven Press, 1981: 303-320.